Claims for Patent: 8,993,511

Summary for Patent: 8,993,511

Title:	.beta.-arrestin effectors and compositions and methods of use thereof
Abstract:	This application describes a family of compounds acting as .beta.-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
Inventor(s):	Yamashita; Dennis (Cambridge, MA), Chen; Xiao-Tao (Furlong, PA)
Assignee:	Trevena, Inc. (King of Prussia, PA)
Application Number:	14/449,647
Patent Claims:	1. A method of treating a cardiovascular disorder in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a peptide, or a pharmaceutically acceptable salt thereof, comprising the sequence of: Sar-Arg-Val-Ww-Zz-His-Pro-Cc, wherein Ww is L-tyrosine, 3-hydroxy-L-tyrosine, 3-fluoro-L-tyrosine, 2,6-difluoro-L-tyrosine, 3-nitro-L-tyrosine, 3,5-dinitro-L-tyrosine, 3-chloro-L-tyrosine, 2,6-dimethyl-L-tyrosine, 4-fluorophenyl-L-alanine, 3,5-dibromo-L-tyrosine, or O-allyl-L-tyrosine; Zz is L-valine or L-isoleucine; and Cc is D-alanine. 2. The method of claim 1, wherein the pharmaceutical composition comprises the peptide, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein Zz is L-isoleucine. 4. The method of claim 2, wherein Ww is L-tyrosine, 3-hydroxy-L-tyrosine, 3-fluoro-L-tyrosine, 2,6-difluoro-L-tyrosine, 3-nitro-L-tyrosine, 3,5-dinitro-L-tyrosine, or 3-chloro-L-tyrosine. 5. The method of claim 4, wherein Zz is L-isoleucine. 6. The method of claim 2, wherein the peptide comprises the sequence of SEQ ID NO: 69, or a pharmaceutically acceptable salt thereof. 7. The method of claim 2, wherein the peptide comprises the sequence of SEQ ID NO: 67, or a pharmaceutically acceptable salt thereof. 8. The method of claim 2, wherein the peptide comprises the sequence of SEQ ID NO:27, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76, or a pharmaceutically acceptable salt thereof. 9. The method of claim 2, wherein the peptide comprises the sequence of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76, or a pharmaceutically acceptable salt thereof. 10. The method of claim 2, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier. 11. The method of claim 2, wherein the pharmaceutical composition comprises sterile water, phosphate buffered saline, or an aqueous glucose solution. 12. The method of claim 1, wherein the cardiovascular disorder is acute heart failure. 13. The method of claim 2, wherein the cardiovascular disorder is heart failure. 14. The method of claim 2, wherein the subject is a subject in need thereof. 15. The method of claim 1, wherein the cardiovascular disorder is selected from the group consisting of acute decompensated heart failure, chronic hypertension, hypertensive crisis, acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency, intracranial hemorrhage, essential hypertension, post-operative hypertension, hypertensive heart disease, hypertensive renal disease, renovascular hypertension, malignant hypertension, post-renal transplant patient stabilization, dilated cardiomyopathy, myocarditis, post-cardiac transplant patient stabilization, disorders associated with post-stent management, neurogenic hypertension, preeclampsia, and abdominal aortic aneurysm. 16. The method of claim 2, wherein the cardiovascular disorder is selected from the group consisting of acute decompensated heart failure, chronic hypertension, hypertensive crisis, acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency, intracranial hemorrhage, essential hypertension, post-operative hypertension, hypertensive heart disease, hypertensive renal disease, renovascular hypertension, malignant hypertension, post-renal transplant patient stabilization, dilated cardiomyopathy, myocarditis, post-cardiac transplant patient stabilization, disorders associated with post-stent management, neurogenic hypertension, preeclampsia, and abdominal aortic aneurysm. 17. The method of claim 14, wherein the heart failure is acute heart failure. 18. The method of claim 2, wherein the pharmaceutical composition is administered intravenously. 19. The method of claim 2, wherein the administration of the pharmaceutical composition maintains glomerular filtration rate in the subject. 20. The method of claim 2, wherein the administration of the pharmaceutical composition decreases vascular resistance in the subject. 21. A method of decreasing renal vascular resistance and/or maintaining glomerular filtration rate in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising a peptide, or a pharmaceutically acceptable salt thereof, comprising the sequence of: Sar-Arg-Val-Ww-Zz-His-Pro-Cc, wherein Ww is L-tyrosine, 3-hydroxy-L-tyrosine, 3-fluoro-L-tyrosine, 2,6-difluoro-L-tyrosine, 3-nitro-L-tyrosine, 3,5-dinitro-L-tyrosine, 3-chloro-L-tyrosine, 2,6-dimethyl-L-tyrosine, 4-fluorophenyl-L-alanine, 3,5-dibromo-L-tyrosine, or O-allyl-L-tyrosine; Zz is L-valine or L-isoleucine; and Cc is D-alanine. 22. The method of claim 21, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier. 23. The method of claim 21, wherein the pharmaceutical composition comprises sterile water, phosphate buffered saline or an aqueous glucose solution. 24. The method of claim 21, wherein the peptide, or a pharmaceutically acceptable salt thereof, comprises the sequence of SEQ ID NO:27, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76. 25. The method of claim 21, wherein the peptide, or a pharmaceutically acceptable salt thereof, comprises the sequence of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76.

Details for Patent 8,993,511

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2028-12-29